LETTER TO THE EDITOR

Humoral responses to BNT162b2 SARS-CoV-2 and hepatitis B vaccines are associated in patients on maintenance hemodialysis: a single-centre experience in Belgium

Elliott Van Regemorter1, Anais Scohy2,3, Johann Morelle1,3, Michel Jadoul1,3 and Laura Labriola1,3

1Division of Nephrology, Cliniques universitaires Saint-Luc, Brussels, Belgium, 2Division of Microbiology, Cliniques universitaires Saint-Luc, Brussels, Belgium and 3Institut de Recherche Expérimentale et Clinique, UCLouvain, Brussels, Belgium

Correspondence to: Laura Labriola; E-mail: Laura.Labriola@uclouvain.be

Maintenance hemodialysis (HD) patients are at high risk for life-threatening coronavirus disease 2019 (COVID-19) [1]. Recent studies have documented a strong humoral response after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in this population [2], even in older patients [3], in contrast to kidney transplant recipients [4]. Previous reports have also shown a poor humoral response after hepatitis B virus (HBV) vaccination in chronic kidney disease patients with comorbidities (e.g. older age, diabetes, immunosuppression) [5,6]. We therefore hypothesized that this weak response to the HBV vaccine could serve as a potential indicator of response to SARS-CoV-2 vaccination. However, data linking humoral responses to both vaccines remains scarce and contradictory [7,8].

We retrospectively studied the association between the humoral response to HBV and BNT162b2 spike mRNA vaccines in a cohort of adult patients on in-centre maintenance (>3 months) HD at Cliniques universitaires Saint-Luc and its satellite site. We excluded 58 patients who had a history or serologic evidence of HBV (n = 27) or SARS-CoV-2 infection (n = 15), refused vaccination (n = 11) or had an incomplete HBV vaccination (n = 5). Demographics, dialysis vintage, diabetes status, immunosuppressive treatment if applicable and time since last SARS-CoV-2 and HBV vaccine administrations were recorded. In each patient, a single sample was tested simultaneously with five electro-chemiluminescent immunoassays (Roche Elecsys): SARS-CoV-2 recombinant nucleocapsid antigen antibody (anti-SARS-CoV-2 N), SARS-CoV-2 spike protein receptor-binding domain antibody (anti-SARS-CoV-2 RBD), hepatitis B surface antigen and antibody (HBsAg and anti-HBs Ab), and hepatitis B core antibody (anti-HBc Ab). Patients were divided into groups depending on their HBV and SARS-CoV-2 vaccine response status. Patients with an anti-HBs Ab titer > 10 IU/mL after three doses of Engerix-B® or Fendrix® and an anti-SARS-CoV-2 RBD Ab titer > 0.8 U/mL after two doses of BNT162b2 SARS-CoV-2 vaccine were considered responders to the HBV and SARS-CoV-2 vaccines, respectively. Groups were compared using unpaired t-test, Mann–Whitney U test and Fisher’s exact test, as appropriate. All tests were two-tailed and a P-value < 0.05 was considered significant.

Fifty-four patients (median age 72 years, 56% men, 91% Caucasians, on dialysis for a median of 47.0 months, 39% diabetics, 19% on immunosuppressive treatment) were included (Table 1). Serum samples were collected 4.1 months [interquartile range (IQR) 4.1–5.0] after the second dose of the SARS-CoV-2 vaccine. Responders to the SARS-CoV-2 vaccine did not differ from non-responders regarding demographics, dialysis vintage and diabetes. However, patients were less likely to respond to the SARS-CoV-2 vaccine if treated with immunosuppressive medications and in case of non-response to the HBV vaccine (Table 1,
Table 1. Characteristics of the patients

| Characteristics                        | All patients (N = 54) | SARS-CoV-2 vaccine responders (N = 49) | SARS-CoV-2 vaccine non-responders (N = 5) | P-value |
|---------------------------------------|-----------------------|---------------------------------------|------------------------------------------|---------|
| Age, median (IQR), years              | 72 (62–81)            | 73 (63–81)                            | 55 (55–67)                               | 0.14    |
| Gender: male, no. (%)                 | 30 (56)               | 27 (55)                               | 3 (60)                                   | 1.00    |
| Race: Caucasian/African, no. (%)      | 49 (91)/5 (9)         | 45 (92)/4 (8)                         | 4 (80)/1 (20)                            | 0.40    |
| Dialysis vintage, median (IQR), months| 47.0 (23.6–78.8)     | 46.2 (23.7–76.6)                      | 68.8 (20.6–110.1)                        | 0.72    |
| Diabetes, no. (%)                     | 21 (39)               | 20 (41)                               | 1 (20)                                   | 0.64    |
| Immunosuppressive treatment, no. (%)  | 10 (19)               | 5 (10)                                | 5 (100)                                  | -0.001  |
| HBV vaccine response, no. (%)         | 39 (72)               | 38 (78)                               | 1 (20)                                   | 0.02    |

Figure 1: Level of anti-HBs Ab (A) and HBV vaccine response status (B) stratified for the presence vs absence of humoral response to SARS-CoV-2 vaccination.

Figure 1). Anti-HBs and anti-SARS-CoV-2 RBD Ab titers were correlated (Spearman, \( r = 0.34, P = 0.01 \)). Out of the five patients who did not respond to the SARS-CoV-2 vaccine, one was on tacrolimus and mycophenolate mofetil, two were on maintenance rituximab and low-dose methylprednisolone, and two were on tacrolimus alone. Out of the five patients on immunosuppressive therapy who responded to the SARS-CoV-2 vaccine, three were on low-dose methylprednisolone and two on tacrolimus alone.

Our study shows a significant association between humoral responses after HBV and SARS-CoV-2 vaccines in a small cohort of patients on maintenance HD. HBV vaccine non-responders may therefore benefit from a systematic SARS-CoV-2 serological follow-up and potential intensification of the vaccine schedule. Furthermore, this study highlights the poor vaccine response of immunosuppressed patients, including those treated with rituximab, as recently reported [9].

A definite strength of this study is its novelty in assessing and correlating immunization responses to both HBV and SARS-CoV-2 vaccines among maintenance HD patients with a subgroup of patients on immunosuppressive therapy. The small sample size is a clear limitation.

**FUNDING**

There was no support/funding for this work.

**CONFLICT OF INTEREST STATEMENT**

This paper has not been published previously in whole or part. L.L. reports lecture fees and travel support from Amgen, and travel support from Vifor Medical Care Pharma and Sanofi-Genzyme. J.M. reports lecture fees from Baxter Healthcare and Fresenius Medical Care, travel support from Sanofi-Genzyme, consulting fees from AstraZeneca, Bayer and Sanofi-Genzyme, and research grants from Baxter Healthcare and Alexion outside the submitted work. M.J. reports grants from AstraZeneca, consulting fees from Astellas, AstraZeneca, Bayer, Boeringher-Ingehelm, Merck, Mundipharma, Fresenius Medical Care Asia Pacific and Vifor Fresenius Medical Care, payments for expert testimony from Vifor Fresenius Medical Care renal Pharma and travel support from Sanofi-Genzyme, outside the submitted work; all grants and fees paid to institution. M.J. is co-chair of KDIGO.

**REFERENCES**

1. Williamson EJ, Walker AJ, Bhaskaran K et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020; 584: 430–436
2. Ikizler TA, Coates PT, Rovin BH, Ronco P. Immune response to SARS-CoV-2 infection and vaccination in patients
receiving kidney replacement therapy. Kidney Int 2021; 99: 1275–1279
3. Labriola L, Scohy A, Van Regemorter E et al. Immunogenicity of BNT162b2 SARS-CoV-2 vaccine in a multicenter cohort of nursing home residents receiving maintenance hemodialysis. Am J Kidney Dis 2021; 78: 766–768
4. Georgery H, Devresse A, Yombi JC et al. Disappointing immunization rate after 2 doses of the BNT162b2 vaccine in a Belgian cohort of kidney transplant recipients. Transplantation; doi: 10.1097/TP.0000000000003861 (online ahead of print)
5. Labriola L, Jadoul M. The decades-long fight against HBV transmission to dialysis patients: slow but definite progress. Nephrol Dial Transplant 2010; 25: 2047–2049
6. Jacobson IM, Jaffers G, Dienstag JL et al. Immunogenicity of hepatitis B vaccine in renal transplant recipients. Transplantation 1985; 39: 393–395
7. Simon B, Rubey H, Treipl A et al. Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared with healthy controls. Nephrol Dial Transplant 2021; 36: 1709–1716
8. Danthu C, Hantz S, Dahlem A et al. Humoral response after SARS-CoV-2 mRNA vaccination in a cohort of hemodialysis patients and kidney transplant recipients. J Am Soc Nephrol 2021; 32: 2153–2158
9. Demoulin N, Scohy A, Gillion V et al. (11 June 2021). Low rates of humoral response to BNT162b2 SARS-CoV-2 vaccination in patients with immune-mediated kidney diseases treated with rituximab. Clin Kidney J; 14: 2132–2133